Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
about
Serotonin 2A receptors contribute to the regulation of risk-averse decisionsSerotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbensThe sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismIn vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the ratDual dopamine/serotonin releasers: potential treatment agents for stimulant addictionFischer 344 and Lewis Rat Strains as a Model of Genetic Vulnerability to Drug AddictionGrowth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target(1,2,3)Molecular and Functional Characterization of Bacopa monniera: A Retrospective ReviewA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesSerotonergic gene variation in substance use pharmacotherapy: a systematic reviewA neural correlate of predicted and actual reward-value information in monkey pedunculopontine tegmental and dorsal raphe nucleus during saccade tasksSerotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorderStimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutationIncreased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brainMice Lacking Serotonin 2C Receptors Have increased Affective Responses to Aversive Stimuli.Elevated Expression of Serotonin 5-HT(2A) Receptors in the Rat Ventral Tegmental Area Enhances Vulnerability to the Behavioral Effects of CocaineThe role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.Opposing effects of 5,7-DHT lesions to the core and shell of the nucleus accumbens on the processing of irrelevant stimuli.Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI ExposureCentral serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward.Molecular targets for treating cognitive dysfunction in schizophrenia.Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway functionNeural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropionImpact of serotonin (5-HT)2C receptors on executive control processes.Data collection and analysis strategies for phMRIRole of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in miceDeep brain stimulation reveals emotional impact processing in ventromedial prefrontal cortex.Abuse potential of carbohydrates for overweight carbohydrate craversA comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?Ethanol is self-administered into the nucleus accumbens shell, but not the core: evidence of genetic sensitivityImpact of RNA editing on functions of the serotonin 2C receptor in vivoHeadache-type adverse effects of NO donors: vasodilation and beyondSerotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?Why psychosis is frequently associated with Parkinson's disease?The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesRole of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersBrain illness and creativity: mechanisms and treatment risks.
P2860
Q23991043-721C2EB9-EC87-4654-ABE4-88CA1A1D3040Q24596784-D16E46F5-3789-4233-9D1F-4DE2EB4A7222Q24614102-F5D22B96-9298-4A67-A720-F5030C01B6BAQ24632527-08FBF60A-EB8B-4874-98DC-8BA2495B827BQ24641896-F0E6EB8D-F513-4660-B85C-1B73D63E07F3Q26768236-703049C0-3421-46F8-A07E-FDB695FB04A6Q26783258-21DE63D8-582E-4776-A777-8CA7890C821EQ26786001-58788F0E-D464-476A-BE38-82640A84C644Q26786354-9D4E177C-0993-49D2-A150-9C74A00E7A4FQ26799093-B62BEE3F-0EFF-4F77-8AB0-AE905332ED9EQ26827751-ADB5EEE7-8C21-4DCF-B09B-8E3C9F3EA7DDQ27015917-4A85337B-23AC-4C86-AD11-19659D51DE37Q28301428-FCA6A98C-7A43-470E-9BC5-0A78E3919BECQ28539770-A033DAE8-E1D0-491C-9AEE-2A3384DB5B5AQ28551249-9C3441B3-4E30-49C5-A77A-276AB92D2190Q29346961-7F3D8A39-151B-4883-A716-EE14FF613552Q30437188-ED3A3975-95EE-49DD-8966-1229817C3677Q30468345-FF298CD5-97C4-4299-B26E-BFBF134D5B0DQ30469931-C157B4AC-FC23-4976-BE18-42C1CD23B355Q30480008-16A86748-4F37-49B5-A076-DE19A35F578FQ30491310-9601B1E9-C7D0-42B3-B5C7-64A96C006847Q30499670-9C4E8062-20AA-4167-87DF-BCC56DCE0A76Q30503382-A86E35FE-81F1-49AF-9F50-EDECBA1D45BEQ30538951-B50F8A37-771E-4C5A-A8FF-73925CB64D67Q30773900-95F93610-EE97-432E-BB12-B2D835D6A45DQ30946517-7D5B84D2-E782-4705-93CD-6681981E7B57Q33517640-39C7276C-C0D9-489F-8020-C92CD0CBBEACQ33691741-08CB6537-1054-44C9-9953-05C399A4C4D6Q33718185-64C88795-82D7-4D82-A422-E2692CAB690BQ33805771-EBCECCF0-4185-4350-9D58-B4A373075E96Q33806232-45DB4FCB-4652-4170-A86B-945A7E23C07EQ33812736-ADCBD8D1-A437-4075-AD49-D947EDF1CB4BQ33874819-90E4EBD7-6688-4F4A-B9FE-D8EF13FBD4F2Q33883890-E1AFAD74-6975-44C6-A33E-C63B1A0A2FEAQ34078777-D9E99647-9269-4161-80CE-E5A079A3D1F4Q34094668-C68E3C4A-C407-465B-B4F0-57CB1459850DQ34112933-9B59DB2E-B4B7-44E6-A5F0-72522522B359Q34122658-51698F30-0C95-410D-B0A8-48CD136799A5Q34166903-F066265A-2C70-452C-ACD7-040B47BC409EQ34173841-7416560B-C4B6-4AB7-A733-D25ED7243240
P2860
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@ast
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@en
type
label
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@ast
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@en
prefLabel
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@ast
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@en
P2860
P1476
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
@en
P2093
P2860
P304
P356
10.1016/J.PHARMTHERA.2006.08.004
P577
2006-10-17T00:00:00Z